Therapy for metastatic melanoma: an overview and update (Q37873464)

24 August 2017

1 reference

title

Therapy for metastatic melanoma: an overview and update (English)

1 reference

24 August 2017

1 reference

1

1 reference

24 August 2017

1 May 2011

1 reference

Expert Review of Anticancer Therapy

24 August 2017

1 reference

24 August 2017

11

1 reference

24 August 2017

5

1 reference

24 August 2017

725-737

1 reference

Final version of 2009 AJCC melanoma staging and classification

24 August 2017

1 reference

Molecular diagnostics in melanoma.

21 January 2018

1 reference

Melanoma and sun exposure: an overview of published studies

21 January 2018

1 reference

A prospective study of pigmentation, sun exposure, and risk of cutaneous malignant melanoma in women.

21 January 2018

1 reference

Adoptive cell therapy for the treatment of patients with metastatic melanoma

21 January 2018

1 reference

Adoptive cell transfer: a clinical path to effective cancer immunotherapy

21 January 2018

1 reference

Small molecules and targeted therapies in distant metastatic disease.

21 January 2018

1 reference

Management of cutaneous melanoma

21 January 2018

1 reference

Chemotherapy by fotemustine in cerebral metastases of disseminated malignant melanoma.

21 January 2018

1 reference

Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study

21 January 2018

1 reference

Phase II randomized trial of cisplatin and WR-2721 versus cisplatin alone for metastatic melanoma: an Eastern Cooperative Oncology Group Study (E1686).

21 January 2018

1 reference

Inefficacy of vindesine monotherapy in advanced stage IV malignant melanoma patients previously treated with other chemotherapeutic agents

21 January 2018

1 reference

Randomized dose-escalation study evaluating peginterferon alfa-2a in patients with metastatic malignant melanoma

21 January 2018

1 reference

Results with methyl-CCNU and DTIC in metastatic melanoma

21 January 2018

1 reference

Combination chemotherapy of dacarbazine and fotemustine in disseminated malignant melanoma. Experience of the French Study Group

21 January 2018

1 reference

A prospective evaluation of a triple-drug regimen containing cisplatin, vinblastine, and dacarbazine (CVD) for metastatic melanoma

21 January 2018

1 reference

Chemotherapy and biologic therapies for melanoma: do they work?

21 January 2018

1 reference

Phase II randomized study of dacarbazine, carmustine, cisplatin and tamoxifen versus dacarbazine alone in advanced melanoma patients.

21 January 2018

1 reference

Phase 2 trial of carboplatin, weekly paclitaxel, and biweekly bevacizumab in patients with unresectable stage IV melanoma: a North Central Cancer Treatment Group study, N047A.

21 January 2018

1 reference

A multicenter phase II clinical trial using dacarbazine and continuous infusion interleukin-2 for metastatic melanoma. Clinical data and immunomonitoring

21 January 2018

1 reference

Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial.

21 January 2018

1 reference

Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial c

21 January 2018

1 reference

Combination chemotherapy with or without s.c. IL-2 and IFN-alpha: results of a prospectively randomized trial of the Cooperative Advanced Malignant Melanoma Chemoimmunotherapy Group (ACIMM)

21 January 2018

1 reference

Cancer. Addiction to oncogenes--the Achilles heal of cancer

21 January 2018

1 reference

Distinct sets of genetic alterations in melanoma

21 January 2018

1 reference

Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi

21 January 2018

1 reference

Mutations in GNA11 in uveal melanoma

21 January 2018

1 reference

Frequent mutations in the MITF pathway in melanoma

21 January 2018

1 reference

Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4.

21 January 2018

1 reference

The proto-oncogene c-kit encoding a transmembrane tyrosine kinase receptor maps to the mouse W locus

21 January 2018

1 reference

Somatic activation of KIT in distinct subtypes of melanoma

21 January 2018

1 reference

Lack of clinical efficacy of imatinib in metastatic melanoma

21 January 2018

1 reference

Phase II trial of imatinib mesylate in patients with metastatic melanoma.

21 January 2018

1 reference

Dose-dependent, complete response to imatinib of a metastatic mucosal melanoma with a K642E KIT mutation

21 January 2018

1 reference

Major response to imatinib mesylate in KIT-mutated melanoma.

21 January 2018

1 reference

Melanoma from bench to bedside: meeting report from the 6th international melanoma congress.

21 January 2018

1 reference

Complete response of stage IV anal mucosal melanoma expressing KIT Val560Asp to the multikinase inhibitor sorafenib

21 January 2018

1 reference

Activity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates

21 January 2018

1 reference

Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies

21 January 2018

1 reference

Malignant melanoma: genetics and therapeutics in the genomic era.

21 January 2018

1 reference

Ultraviolet radiation and melanoma: a systematic review and analysis of reported sequence variants

21 January 2018

1 reference

Differential oncogenic potential of activated RAS isoforms in melanocytes

21 January 2018

1 reference

The product of ras is a GTPase and the T24 oncogenic mutant is deficient in this activity.

21 January 2018

1 reference

Genetic alterations in signaling pathways in melanoma

21 January 2018

1 reference

PTEN signaling pathways in melanoma

21 January 2018

1 reference

Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma

21 January 2018

1 reference

Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma.

21 January 2018

1 reference

PI3-kinase subunits are infrequent somatic targets in melanoma.

21 January 2018

1 reference

A novel AKT3 mutation in melanoma tumours and cell lines

21 January 2018

1 reference

Integrated Molecular and Clinical Analysis of AKT Activation in Metastatic Melanoma

21 January 2018

1 reference

CCI-779 in metastatic melanoma: a phase II trial of the California Cancer Consortium

21 January 2018

1 reference

mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt

21 January 2018

1 reference

The PI3K pathway as drug target in human cancer

21 January 2018

1 reference

Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance

21 January 2018

1 reference

Combined targeting of BRAF and CRAF or BRAF and PI3K effector pathways is required for efficacy in NRAS mutant tumors

21 January 2018

1 reference

Mutations of the BRAF gene in human cancer

21 January 2018

1 reference

The RAF proteins take centre stage

21 January 2018

1 reference

BRAF as therapeutic target in melanoma

21 January 2018

1 reference

Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF

21 January 2018

1 reference

High frequency of BRAF mutations in nevi

21 January 2018

1 reference

Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF

21 January 2018

1 reference

Wild-type and mutant B-RAF activate C-RAF through distinct mechanisms involving heterodimerization

21 January 2018

1 reference

In melanoma, RAS mutations are accompanied by switching signaling from BRAF to CRAF and disrupted cyclic AMP signaling

21 January 2018

1 reference

CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations

21 January 2018

1 reference

B-RAF is a therapeutic target in melanoma

21 January 2018

1 reference

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

21 January 2018

1 reference

Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis

21 January 2018

1 reference

Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group

21 January 2018

1 reference

Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma

21 January 2018

1 reference

Design and synthesis of orally bioavailable benzimidazoles as Raf kinase inhibitors

21 January 2018

1 reference

Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885

21 January 2018

1 reference

Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity

21 January 2018

1 reference

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

21 January 2018

1 reference

COT drives resistance to RAF inhibition through MAP kinase pathway reactivation

21 January 2018

1 reference

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

21 January 2018

1 reference

Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K

21 January 2018

1 reference

PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF melanoma cells

21 January 2018

1 reference

BRAF mutation predicts sensitivity to MEK inhibition

21 January 2018

1 reference

Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies

21 January 2018

1 reference

Phase I pharmacokinetic and pharmacodynamic study of the oral MAPK/ERK kinase inhibitor PD-0325901 in patients with advanced cancers

21 January 2018

1 reference

Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers

21 January 2018

1 reference

The first-in-human study of the hydrogen sulfate (Hyd-sulfate) capsule of the MEK1/2 inhibitor AZD6244 (ARRY-142886): a phase I open-label multicenter trial in patients with advanced cancer

21 January 2018

1 reference

Clinical and biological efficacy of recombinant human interleukin-21 in patients with stage IV malignant melanoma without prior treatment: a phase IIa trial.

21 January 2018

1 reference

CTLA-4 is constitutively expressed on tumor cells and can trigger apoptosis upon ligand interaction

21 January 2018

1 reference

Immune checkpoint proteins: a new therapeutic paradigm for cancer--preclinical background: CTLA-4 and PD-1 blockade

21 January 2018

1 reference

Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade

21 January 2018

1 reference

Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4

21 January 2018

1 reference

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates

21 January 2018

1 reference

A comprehensive catalogue of somatic mutations from a human cancer genome

21 January 2018

1 reference

Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma

21 January 2018

1 reference

MEK1 mutations confer resistance to MEK and B-RAF inhibition

21 January 2018

1 reference

Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy.

21 January 2018

1 reference

Phase I/II trial of tremelimumab in patients with metastatic melanoma

21 January 2018

1 reference

Industry makes strides in melanoma

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1586/ERA.11.25

1 reference

24 August 2017

1 reference

PubMed ID

21554048